Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous Routes

被引:124
作者
Bonilla, Francisco A. [1 ,2 ]
机构
[1] Childrens Hosp, Div Immunol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA
关键词
Immunoglobulin; Intravenous; Pharmacokinetics; Subcutaneous;
D O I
10.1016/j.iac.2008.06.006
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
This article reviews pharmacokinetic studies of IgG administration by intravenous and subcutaneous routes. Intravenous immunoglobulin pharmacokinetics have been studied during replacement therapy for primary and secondary immunodeficiencies and other special circumstances (eg, infection prophylaxis in neonates). Subcutaneous immunoglobulin pharmacokinetics have been studied only during replacement therapy for primary immunodeficiency. Published studies vary greatly with respect to the nature of the patients studied, dose regimens, sampling schedules, and pharmacokinetic models, making comparisons difficult. With either route of administration, there is large variation in individual IgG elimination rates. Periodic measurement of serum IgG concentration is critical to monitor the adequacy of replacement during therapy.
引用
收藏
页码:803 / 819
页数:17
相关论文
共 49 条
[1]   Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes [J].
Alyanakian, MA ;
Bernatowska, E ;
Scherrmann, JM ;
Aucouturier, P ;
Poplavsky, JL .
VOX SANGUINIS, 2003, 84 (03) :188-192
[2]   Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex™, 10%) [J].
Ballow, M ;
Berger, M ;
Bonilla, FA ;
Buckley, RH ;
Cunningham-Rundles, CH ;
Fireman, P ;
Kaliner, M ;
Ochs, HD ;
Skoda-Smith, S ;
Sweetser, MT ;
Taki, H ;
Lathia, C .
VOX SANGUINIS, 2003, 84 (03) :202-210
[3]   Subcutaneous immunoglobulin replacement in primary immunodeficiencies [J].
Berger, M .
CLINICAL IMMUNOLOGY, 2004, 112 (01) :1-7
[4]   Safety, efficacy, and pharmacokinetics of Flebogamma® 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases [J].
Berger, M ;
Pinciaro, PJ .
JOURNAL OF CLINICAL IMMUNOLOGY, 2004, 24 (04) :389-396
[5]   A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma® 5% DIF, the next generation of Flebogamma® [J].
Berger, Melvin .
JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (06) :628-633
[6]   Clinical properties of a novel liquid intravenous immunoglobulin:: Studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies [J].
Borte, M ;
Davies, SV ;
Touraine, JL ;
Farber, CM ;
Lipsic, T ;
Adams, C ;
Späth, P ;
Bolli, R ;
Morell, A ;
Andresen, I .
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2004, 31 (03) :126-134
[7]  
BOSI A, 1990, HAEMATOLOGICA, V75, P109
[8]   THEORETICAL MODEL OF GAMMA-GLOBULIN CATABOLISM [J].
BRAMBELL, FW ;
HEMMINGS, WA ;
MORRIS, IG .
NATURE, 1964, 203 (495) :1352-&
[9]  
Chapel H M, 1993, Immunodeficiency, V4, P77
[10]   INTRAVENOUS GAMMA-GLOBULIN THERAPY FOR PROPHYLAXIS OF INFECTION IN HIGH-RISK NEONATES [J].
CHIRICO, G ;
RONDINI, G ;
PLEBANI, A ;
CHIARA, A ;
MASSA, M ;
UGAZIO, AG .
JOURNAL OF PEDIATRICS, 1987, 110 (03) :437-442